CRIS Current Research Information System

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.179
AS - Asia 2.283
EU - Europa 1.858
AF - Africa 149
SA - Sud America 119
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.148
VN - Vietnam 693
SG - Singapore 661
CN - Cina 518
GB - Regno Unito 475
SE - Svezia 328
DE - Germania 231
IT - Italia 226
FR - Francia 121
HK - Hong Kong 117
IN - India 114
RU - Federazione Russa 100
BR - Brasile 83
IE - Irlanda 83
NL - Olanda 47
CI - Costa d'Avorio 42
FI - Finlandia 42
JP - Giappone 39
ZA - Sudafrica 39
EE - Estonia 38
UA - Ucraina 38
TG - Togo 33
CH - Svizzera 29
BG - Bulgaria 25
KR - Corea 25
BE - Belgio 24
JO - Giordania 19
CA - Canada 17
NG - Nigeria 14
PH - Filippine 14
AR - Argentina 12
BD - Bangladesh 11
AT - Austria 10
GR - Grecia 10
TR - Turchia 10
EC - Ecuador 9
PL - Polonia 9
TH - Thailandia 9
IR - Iran 8
MX - Messico 8
TW - Taiwan 8
ID - Indonesia 6
IQ - Iraq 6
AU - Australia 5
MA - Marocco 5
PK - Pakistan 5
SA - Arabia Saudita 5
SC - Seychelles 5
CO - Colombia 4
CZ - Repubblica Ceca 4
ES - Italia 4
UZ - Uzbekistan 4
DZ - Algeria 3
EG - Egitto 3
LB - Libano 3
LT - Lituania 3
PE - Perù 3
RO - Romania 3
BO - Bolivia 2
CL - Cile 2
CY - Cipro 2
ET - Etiopia 2
GT - Guatemala 2
MY - Malesia 2
OM - Oman 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
CR - Costa Rica 1
DK - Danimarca 1
EU - Europa 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
MG - Madagascar 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 7.595
Salva come PNG Salva come JPEG
Città #
Singapore 457
Southend 416
Fairfield 397
Ashburn 333
Chandler 253
Dong Ket 205
Seattle 184
San Jose 169
Woodbridge 168
Houston 161
Cambridge 156
Wilmington 143
Ann Arbor 137
Ho Chi Minh City 112
Hong Kong 112
Hanoi 99
Princeton 92
Santa Clara 87
Dublin 83
Beijing 78
Boardman 55
Lauterbourg 44
Nanjing 44
Abidjan 42
Westminster 42
Hefei 41
Bologna 38
Los Angeles 37
Padova 37
Helsinki 36
Tokyo 36
Lomé 33
Bremen 32
Jinan 32
New York 32
Berlin 25
Bern 25
Shenyang 25
Sofia 25
Brussels 24
Frankfurt am Main 22
Dallas 21
Saint Petersburg 20
Seoul 20
Amman 19
Buffalo 18
Milan 18
Munich 18
Redondo Beach 16
San Diego 16
Turin 16
Haiphong 14
Abeokuta 13
Chicago 13
Falls Church 13
Da Nang 12
Guangzhou 12
Changsha 11
Hyderabad 11
Jacksonville 11
London 11
Orem 11
Zhengzhou 11
Council Bluffs 10
Dearborn 10
Hebei 10
São Paulo 9
Tianjin 9
Nanchang 8
Norwalk 8
Redmond 8
Brooklyn 7
Florence 7
Hangzhou 7
Olalla 7
Paris 7
Phoenix 7
Redwood City 7
Shanghai 7
Biên Hòa 6
Boston 6
Des Moines 6
Fremont 6
Can Tho 5
Columbus 5
Falkenstein 5
Fuzhou 5
Haikou 5
Istanbul 5
Kunming 5
Kyiv 5
Ningbo 5
Taiyuan 5
The Dalles 5
Turku 5
Vienna 5
Bengaluru 4
Chengdu 4
Farra d'Isonzo 4
Harbin 4
Totale 5.127
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 257
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 243
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 238
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
A case report of acute myeloid leukemia and neurofibromatosis 1 220
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 220
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 213
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 204
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 187
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 185
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 183
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 183
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 183
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 179
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 179
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 175
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 167
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 165
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 162
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 155
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 154
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 154
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 140
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 139
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 137
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 136
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 135
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 134
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 130
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 127
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 125
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors 122
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 122
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 120
The CD47 pathway is deregulated in human immune thrombocytopenia 113
null 98
null 96
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 93
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 91
null 86
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 86
Totale 7.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021409 0 0 0 0 0 0 0 0 0 51 32 326
2021/2022945 75 36 45 113 87 47 29 46 39 114 169 145
2022/20231.027 109 164 63 144 54 81 31 63 176 42 53 47
2023/2024246 14 42 28 29 20 58 4 10 6 16 8 11
2024/2025904 46 166 82 84 122 37 56 26 25 69 36 155
2025/20261.957 175 149 189 144 212 136 194 147 474 137 0 0
Totale 7.745